cladribine has been researched along with Recrudescence in 140 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 32 (22.86) | 18.2507 |
| 2000's | 43 (30.71) | 29.6817 |
| 2010's | 35 (25.00) | 24.3611 |
| 2020's | 30 (21.43) | 2.80 |
| Authors | Studies |
|---|---|
| Herbaux, C; Montes, L | 1 |
| Celius, EG; Høgestøl, EA; Myhr, KM; Nygaard, GO; Skattebøl, L; Sowa, P; Torgauten, H; Torkildsen, Ø | 1 |
| Atula, S; Järvinen, E; Kuusisto, H; Rauma, I; Ryytty, M; Sipilä, JOT; Soilu-Hänninen, M; Viitala, M | 1 |
| DU, Y; Li, H; Li, JX; Lu, WJ; Qi, SS; Tao, F; Xiong, H; Yang, L; Zhang, LN | 1 |
| Aslan, D; Hackert, J; Hagenacker, T; Huntemann, N; Kleinschnitz, C; Kleinschnitz, K; Meuth, SG; Pawlitzki, M; Pfeuffer, S; Pul, R; Rolfes, L; Ruck, T; Schmidt, M; Skuljec, J; Su, C | 1 |
| Anastasia, A; Annibali, O; Broccoli, A; Cantonetti, M; Casadei, B; Criscuolo, M; De Luca, ML; Deodato, M; Falini, B; Fianchi, L; Frustaci, A; Galli, E; Guarnera, L; Kovalchuk, S; Marchesi, F; Motta, M; Nizzoli, ME; Offidani, M; Olivieri, A; Orsucci, L; Pagano, L; Piciocchi, A; Pulsoni, A; Sarlo, C; Simonetti, E; Spolzino, A; Stelitano, C; Storti, S; Tiacci, E; Trentin, L; Varettoni, M; Vassallo, F; Visentin, A; Volpetti, S; Zinzani, PL | 1 |
| Butler, E; Butzkueven, H; Buzzard, K; Eichau, S; Girard, M; Hodgkinson, S; Jokubaitis, V; Kalincik, T; Lechner-Scott, J; Monif, M; Oh, J; Prevost, J; Skibina, O; van der Walt, A; Van Pesch, V; Zhong, M | 1 |
| Damian, D; Dangond, F; Galazka, A; Harty, G; Jack, D; Vermersch, P; Wong, SL | 2 |
| Alexandri, N; Coyle, PK; Dangond, F; Galazka, A; Giovannoni, G; Leist, TP; Rammohan, K; Sormani, MP; Stefano, N | 1 |
| Fleifel, L; Khamis, C; Koussa, S; Matni, M; Mohamed, O; Sharifi, S; Yamout, B | 1 |
| Alroughani, R; Barnett, M; Boz, C; Butzkueven, H; Hodgkinson, S; Horakova, D; Izquierdo, G; Jokubaitis, V; Kalincik, T; Karabudak, R; Khoury, SJ; Kubala Havrdova, E; Kuhle, J; Lechner-Scott, J; Macdonell, R; Merlo, D; Monif, M; Onofrj, M; Ozakbas, S; Patti, F; Prat, A; Prevost, J; Roos, I; Skibina, O; Slee, M; van der Walt, A; Van Pesch, V; Zhou, Z; Zhu, C | 1 |
| Ciplea, AI; Dost-Kovalsky, K; Gold, R; Hellwig, K; Thiel, S | 1 |
| Al-Asmi, A; Alroughani, R; Altintas, A; Ampapa, R; Blanco Morgado, Y; Butzkueven, H; Gerlach, O; Hodgkinson, S; Horakova, D; Kalincik, T; Kuhle, J; Laureys, G; Lechner-Scott, J; Macdonell, R; Oh, J; Ozakbas, S; Patti, F; Sanchez-Menoyo, JL; Soysal, A; Spelman, T; Spitaleri, D; Terzi, M; Tundia, N; Van Der Walt, A; van Pesch, V; Wong, SL; Yamout, B | 1 |
| Brownlee, W; Celius, EG; Centonze, D; Giovannoni, G; Havrdova, EK; Hodgkinson, S; Kleinschnitz, C; Magyari, M; Oreja-Guevara, C; Salloukh, H; Selchen, D; Van Wijmeersch, B; Vermersch, P; Wiendl, H; Yamout, B | 1 |
| Chen, FF; Cui, L; Huang, XT; Li, ZG; Lian, HY; Ma, HH; Wang, CJ; Wang, D; Wang, TY; Wei, A; Yang, Y; Zhang, L; Zhang, Q; Zhang, R; Zhu, T | 1 |
| Huang, L; Huang, W; Jin, J; Li, L; Li, M; Li, Y; Mao, X; Meng, F; Peng, Y; Tong, X; Xu, B; Zhang, D | 1 |
| Buchmann, A; Feige, J; Harrer, A; Hilpold, P; Hitzl, W; Khalil, M; Machegger, L; Moser, T; Seiberl, M; Trinka, E; Wipfler, P | 1 |
| Ferrè, L; Filippi, M; Martinelli, V; Meani, A; Moiola, L; Rocca, MA; Zanetta, C | 1 |
| Aerts, S; Khan, H; Peeters, LM; Popescu, V; Severijns, D; Van Wijmeersch, B | 1 |
| Brownlee, WJ; Duncan, J; Haghikia, A; Harty, GT; Hayward, B; Kayaniyil, S; Khan, Z; Millar, S; Waser, N | 1 |
| Song, Y; Sundar, M; Tundia, N; Wang, Y; Wong, SL; Yang, D | 1 |
| Álvarez-Cermeño, JC; Estrada-Pérez, V; Fernández, O; García-Merino, JA; Izquierdo, G; Oreja-Guevara, C; Rodríguez-Antigüedad, A; Saiz, A | 1 |
| Caire-Herrera, LE; Casallas-Vanegas, A; Coss-Rovirosa, F; Flores-Rivera, J; Gómez-Figueroa, E; Salado-Burbano, J | 1 |
| Brossart, P; Glasmacher, A; Hahn-Ast, C; Mayer, K; Schmidt-Wolf, IGH; Schwab, K; von Lilienfeld-Toal, M | 1 |
| Allen-Philbey, K; Baker, D; De Trane, S; Giovannoni, G; Mateo-Casas, M; Mathews, J; O'Toole, EA; Reyes, S; Schmierer, K; Yildiz, O | 1 |
| Bayas, A; Kallmann, B; Kleinschnitz, C; Linker, R; Mäurer, M; Meuth, SG; Rieckmann, P | 1 |
| AbdelRaheem, HG; Elsantiel, HIE; Elsherif, NHK; Makkeyah, SM; Ragab, IA; Tantawy, AAG | 1 |
| Adlard, N; Cameron, C; Drudge, C; Häring, DA; Klotz, L; Samjoo, IA; Stoneman, D; Worthington, E; Zhao, M | 1 |
| Alexandri, N; Coyle, PK; Dangond, F; De Stefano, N; Galazka, A; Giovannoni, G; Keller, B; Leist, T; Rammohan, K; Sormani, MP | 1 |
| Comi, G; Dangond, F; Giovannoni, G; Jack, D; Keller, B; Rammohan, K; Rieckmann, P; Vermersch, P | 1 |
| Beiki, O; Clerico, M; Del Giovane, C; Filippini, G; Fredrikson, S; Mattoscio, M; Piazza, F; Salanti, G; Scalfari, A; Tramacere, I | 1 |
| Alexander, TB; Inaba, H; Pounds, S; Pui, CH; Ribeiro, RC; Rubnitz, JE; Triplett, BM; Wang, L | 1 |
| Barnett, M; Butler, E; Butzkueven, H; Duquette, P; Fabis-Pedrini, M; Ferraro, D; Girard, M; Grammond, P; Grand'Maison, F; Havrdova, E; Hodgkinson, S; Horakova, D; Hupperts, R; Jokubaitis, V; Kalincik, T; Kermode, A; Lechner-Scott, J; Lugaresi, A; McCombe, P; Prat, A; Prevost, J; Shaw, C; Slee, M; Sola, P; Solaro, C; Spelman, T; Terzi, M; Trojano, M | 1 |
| Dangond, F; Hicking, C; Munafo, A; Terranova, N | 1 |
| Mitsikostas, DD; Papadopoulos, D | 1 |
| Lv, T; Tian, X; Wang, L; Xu, J; Yuan, G | 1 |
| Alonso-Magdalena, L; Dangond, F; Galazka, A; Martinelli, V; Pfleger, C; Phillips, L; Rieckmann, P; Vermersch, P | 1 |
| Burian, C; Rosenberg, JD; Saven, A; Waalen, J | 1 |
| Abboud, CN; Cashen, A; Dipersio, JF; Fiala, M; McBride, A; Ramsingh, G; Stockerl-Goldstein, K; Uy, G; Vij, R; Westervelt, P | 1 |
| Brousse, N; Brouzes, C; Delarue, R; Derrieux, C; Emile, JF; Gibault, L; Hermine, O; Kaltenbach, S; Michonneau, D; North, MO; Trinquand, A; Varet, B | 1 |
| Jain, P; Pemmaraju, N; Ravandi, F | 1 |
| Cortes, JE; Feldman, EJ; Goldberg, SL; Hogge, DE; Kantarjian, H; Kolitz, JE; Larson, M; Louie, AC; Pigneux, A; Recher, C; Rizzeri, DA; Schiller, G; Warzocha, K | 1 |
| Freyer, CW; Gupta, N; Wang, ES; Wetzler, M | 1 |
| Abdel-Wahab, O; Salam, L | 1 |
| Qing, S; Weihong, Z; Xintian, L; Yao, X; Ying, H | 1 |
| Arico, M; Armari Alla, C; Bardet, O; Barkaoui, M; Bernard, F; Clausen, N; Donadieu, J; Gandemer, V; Henter, JI; Jeziorski, E; Lambilliote, A; Mura, R; Piguet, C; Van Den Bos, C; van Noesel, M; Weitzman, S | 1 |
| Dearden, C | 1 |
| Catovsky, D; Dearden, CE; Else, M | 1 |
| Ravandi, F | 1 |
| Brandt, M; Burger, J; Chihara, D; Faderl, S; Ferrajoli, A; Jain, P; Jorgensen, J; Kantarjian, H; Keating, M; Luthra, R; O'Brien, S; Pierce, S; Poku, R; Ravandi, F; Thompson, P | 1 |
| Duan, MH; Feng, J; Han, X; Li, J; Tian, LP; Yang, C; Zhang, L; Zhang, M; Zhang, W; Zhang, Y; Zhou, DB | 1 |
| Bang, SM; Kim, I; Koh, Y; Lee, JO; Park, H; Park, S; Yoon, SS; Youk, J | 1 |
| Fridle, C; Manz, MG; Medinger, M; Pabst, T; Passweg, J; Seipel, K; Wilk, MC | 1 |
| Abboud, C; Becker, M; Friedberg, J; Ifthikharuddin, J; Komrokji, RS; Liesveld, JL; Messina, P; Mulford, D; Oliva, J; Phillips, G; Walker, AR | 1 |
| Bargetzi, M; Gratwohl, A; Hess, U; Simcock, M; Tobler, A; Zenhäusern, R | 1 |
| Apollonsky, N; Lipton, JM | 1 |
| Catovsky, D; Dearden, CE; Else, M; Forconi, F; Garcia-Talavera, J; Haynes, A; Johnson, SA; Lauria, F; Matutes, E; O'Connor, NT; Osuji, N; Rohatiner, AZ | 1 |
| Itoh, K; Kasai, M; Maruyama, D; Matsuno, Y; Matsusako, M; Mori, S; Morishima, Y; Nakamura, S; Nakata, M; Nawano, S; Ogura, M; Ohashi, Y; Tanimoto, K; Terauchi, T; Tobinai, K; Usui, N; Watanabe, T | 1 |
| Abboud, CN; Augustin, K; DiPersio, JF; Hladnik, L; Martin, MG; Welch, JS | 1 |
| Fitzgerald, DJ; Kreitman, RJ; Pastan, I | 1 |
| Crews, KR; Inaba, H; Pounds, S; Pui, CH; Razzouk, BI; Ribeiro, RC; Rubnitz, JE; Stewart, CF; Yang, S | 1 |
| Ishitsuka, K; Katayose, K; Kimura, N; Ogata, K; Sasaki, H; Suzumiya, J; Takamatsu, Y; Tamura, K | 1 |
| Bonzano, L; De Stefano, N; Roccatagliata, L; Sormani, MP | 1 |
| Inoue, M; Kawa, K; Nakayama, M; Sawada, A; Yamada, K; Yasui, M | 1 |
| Andreola, G; Fabbri, A; Laszlo, D; Martinelli, G; Negri, M; Pinto, A; Rabascio, C; Rigacci, L | 1 |
| Ahmad, H; Catovsky, D; Dearden, CE; Else, M; Forconi, F; Kelly, S; Lauria, F; Liyanage, A; Matutes, E; Ratnayake, V; Shankari, J; Whalley, I | 1 |
| Naik, RR; Saven, A | 1 |
| Adam, Z; Adamová, Z; Brejcha, M; Hájek, R; Kodet, R; Koukalová, R; Krejčí, M; Mayer, J; Moulis, M; Nebeský, T; Pour, L; Rehák, Z; Szturz, P; Zahradová, L | 1 |
| Adamkiewicz-Drożyńska, E; Bączek, T; Balcerska, A; Belka, M; Konieczna, L; Maciejka-Kapuścińska, L; Niedźwiecki, M; Wachowiak, J; Wiśniewski, J | 1 |
| Alarcón-Urdaneta, C; Calderón-García, J; Gómez-Almaguer, D; Ruiz-Argüelles, GJ; Ruiz-Delgado, GJ; Tarín-Arzaga, LC | 1 |
| Al'-Radi, LS; Kravchenko, SK; Pivnik, AV; Zingerman, BV | 1 |
| Felstead, AM; Hughes, CW; Main, BG; Thomas, SJ | 1 |
| Boński, JZ; Dmoszyńska, A; Dwilewicz-Trojaczek, J; Góra-Tybor, J; Hellmann, A; Kasznicki, M; Konopka, L; Robak, T; Wołowiec, D | 1 |
| Betticher, D; Cerny, T; Fey, MF; Frickhofen, N; Ghielmini, M; Hess, U; Konwalinka, G; Piguet, D; Racine, C; Rufener, B; Schmitz, SF; Tichelli, A; Tobler, A; von Rohr, A; Wernli, M; Zulian, G | 1 |
| Creutzig, U; Hählen, K; Harbott, J; Huismans, DR; Kaspers, GJ; Pieters, R; Slater, RM; Veerman, AJ; Zimmermann, M; Zwaan, CM | 1 |
| Del Vecchio, L; Ferrara, F; Morabito, P; Palmieri, S; Pocali, B; Pollio, F; Scalia, G | 1 |
| Kami, M; Kanda, Y; Makimoto, A; Mineishi, S; Nakai, K; Saito, T; Takaue, Y; Tanosaki, R; Tobinai, K; Wakasugi, H | 1 |
| Bányai, A; Gopcsa, L; Karádi, A; Matolcsy, A; Pálóczi, K; Tamáska, J | 1 |
| Dmoszyńska, A; Grosicki, S; Hellmann, A; Hołowiecki, J; Jedrzejczak, W; Kowal, M; Kuliczkowski, K; Kyrcz-Krzemień, S; Lech-Marańda, E; Maj, S; Robak, T; Skotnicki, A; Wierzbowska, A; Wrzesień-Kuś, A | 1 |
| Hamaki, T; Heike, Y; Hori, A; Imataki, O; Kami, M; Kim, SW; Kishi, Y; Kojima, R; Masuo, S; Miyakoshi, S; Murashige, N; Onishi, Y; Sakiyama, M; Takaue, Y; Taniguchi, S; Tanosaki, R; Tobinai, K | 1 |
| Pui, CH; Razzouk, BI; Ribeiro, RC; Rubnitz, JE; Santana, VM; Srivastava, DK | 1 |
| Fietz, T; Knauf, W; Rieger, K; Schmittel, A; Thiel, E | 1 |
| Chou, T; Kasai, M; Kobayashi, Y; Matsuno, Y; Miura, I; Mori, S; Morishima, Y; Murayama, T; Nakamura, S; Ogura, M; Ohashi, Y; Sugai, S; Tobinai, K; Uike, N | 1 |
| Tallman, MS; Zakarija, A | 1 |
| Badowska, W; Balcerska, A; Balwierz, W; Czyzewski, K; Debski, R; Juraszewska, E; Konatkowska, B; Kowalczyk, J; Krawczuk-Rybak, M; Kuzmicz, M; Malinowska, I; Matysiak, M; Olejnik, I; Ploszynska, A; Sońta-Jakimczyk, D; Stanczak, E; Stefaniak, J; Styczynski, J; Szczepanski, T; Wachowiak, J; Wieczorek, M; Wysocki, M | 1 |
| Chadha, P; Evanchuk, DM; Hakimian, D; Kim, B; Mendiratta, P; Peterson, LC; Rademaker, AW; Tallman, MS | 1 |
| Błoński, JZ; Chojnowski, K; Kasznicki, M; Robak, T; Szmigielska-Kapłon, A | 1 |
| Gratwohl, A; Rimner, T; Tichelli, A; Went, P | 1 |
| Faderl, S; Ferrajoli, A; Freireich, EJ; Giles, FJ; Huang, X; Jones, D; Jorgensen, JL; Kantarjian, HM; Keating, MJ; Koller, CA; O'Brien, SM; Odinga, S; Ravandi, F; Thomas, DA; Verstovsek, S; Wierda, WG | 1 |
| Belani, R; Saven, A | 1 |
| Grever, MR | 1 |
| Inamoto, Y; Ito, M; Kodera, Y; Kuwatsuka, Y; Miyamura, K; Murase, T; Oba, T; Suzuki, R; Terakura, S; Tokunaga, M; Tsujimura, A | 1 |
| Gidron, A; Tallman, MS | 1 |
| Błoński, JZ; Cebula, B; Grzybowska-Izydorczyk, O; Robak, T; Smolewski, P | 1 |
| Catovsky, D; Dearden, C; Del Giudice, I; Else, M; Forconi, F; Lauria, F; Matutes, E; Osuji, N; Wotherspoon, A | 1 |
| Cebula, B; Giebel, S; Grosicki, S; Hołowiecki, J; Kiełbiński, M; Kuliczkowski, K; Kyrcz-Krzemień, S; Kłoczko, J; Piatkowska-Jakubas, B; Pluta, A; Robak, T; Skotnicki, AB; Wawrzyniak, E; Wierzbowska, A; Wrzesień-Kuś, A; Zawilska, K | 1 |
| Bauer, F; Beham-Schmid, C; Brezinschek, R; Jaeger, G; Mannhalter, C; Neumeister, P | 1 |
| Alexanian, R; Dimopoulos, MA; Kantarjian, H; Keating, M; Weber, DM | 1 |
| Betticher, D; Cerny, T; Dallafior, S; Hauser, C; Pugin, P; Saurat, JH | 1 |
| Ellison, D; Emanuele, S; Kosty, M; Koziol, J; Piro, L; Saven, A | 1 |
| Hakimian, D; Hogan, DK; Rademaker, A; Rose, E; Tallman, MS; Variakojis, D; Zanzig, C | 1 |
| Alexanian, R; Delasalle, KB; Dimopoulos, MA; Keating, M; Weber, D | 1 |
| Alexanian, R; Cabanillas, F; Delasalle, K; Dimopoulos, MA; Estey, E; Kantarjian, H; Keating, M; O'Brien, S; Rose, E; Weber, D | 1 |
| Juliusson, G; Liliemark, J | 1 |
| Catovsky, D; Coles, H; Emmett, E; Matutes, E; Mercieca, J | 1 |
| Busuttil, DP; Chasty, RC; Copplestone, JA; Fraser, M; Prentice, AG | 1 |
| Krykowski, E; Robak, T; Warzocha, K | 1 |
| Andreeff, HM; Beran, M; Estey, E; Gandhi, V; Kantarjian, HM; Koller, CA; Kornblau, SM; O'Brien, S; Plunkett, W | 1 |
| Bashford, J; Bunce, I; Dodds, A; Eliadis, P; Firkin, F; Frost, T; Goldstein, D; Grigg, A; Kelly, C; Kimber, R; Lee, N; Lowenthal, R; Moore, D; Morton, J; Mulligan, S; Parkin, J; Rentoul, A; Rodwell, R; Rooney, K; Stone, J; Taylor, K; Wright, S | 1 |
| Błasinka-Morawiec, M; Ceglarek, B; Dmoszynska, A; Durzynski, T; Dwilewicz-Trojaczek, J; Grieb, P; Hansz, J; Hellmann, A; Kasznicki, M; Komarnicki, M; Konopka, L; Kopec, I; Kotlarek-Haus, S; Krykowski, E; Lewandowski, K; Maj, S; Mazur, G; Potemski, P; Płuzanska, A; Robak, T; Sikorska, A; Skotnicki, AB; Urasinski, I; Zaucha, JM; Zdziarska, B | 1 |
| Algeri, R; Birtolo, S; Forconi, F; Galieni, P; Lauria, F; Raspadori, D; Rondelli, D; Tura, S; Ventura, MA; Zinzani, PL | 1 |
| Hoffman, MA; Janson, D; Rai, KR; Rose, E | 1 |
| Blasińska-Morawiec, M; Hellmann, A; Krykowski, E; Robak, T; Urbańska-Ryś, H | 1 |
| Bergmann, L | 1 |
| Hilgenfeld, E; Jäger, U; Knauf, WU; Mitterbauer, M; Wilfing, A | 1 |
| Becton, DL; Saylors, RL; Stine, KC; Williams, LL | 1 |
| Delannoy, A; Doyen, C; Ferrant, A; Martiat, P; Michaux, JL; Mineur, P; Van Den Neste, E; Zenebergh, A | 1 |
| Haanen, C; Idink-Mecking, CA; Reutelingsperger, C; Richel, DJ; Schaafsma, MR; Vermes, I | 1 |
| Burian, C; Liu, ES; Miller, WE; Saven, A | 1 |
| Bobzien, W; Lepera, P; Sallah, S; Sallah, W; Wehbie, R | 1 |
| Bergmann, L; Chow, KU; Hansmann, ML; Hoelzer, D; Hossfeld, DK; Jäger, E; Meyer, A; Mitrou, PS; Peters, HD; Rummel, MJ | 1 |
| Bartl, R; Dietzfelbinger, H; Heinemann, V; Hill, W; Jehn, U; Vehling-Kaiser, U; Wolf-Hornung, B | 1 |
| Błasińska-Morawiec, M; Błoński, JZ; Robak, T; Skotnicki, AB; Urbańska-Ryś, H | 1 |
| Cassileth, PA; Foucar, K; Grever, M; Habermann, T; Hakimian, D; Kopecky, KJ; Peterson, LC; Rowe, JM; Tallman, MS; Wheaton, S; Wollins, E | 1 |
| Bosanquet, AG; Copplestone, JA; Johnson, SA; Orchard, JA; Oscier, DG; Povey, SJ; Smith, AG | 1 |
| Catovsky, D; Dearden, CE; Hilditch, BL; Matutes, E; Swansbury, GJ | 1 |
| Bergmann, L; Chow, KU; Hansmann, ML; Hoelzer, D; Hossfeld, DK; Jäger, E; Leimer, L; Meyer, A; Mitrou, PS; Peters, HD; Rummel, MJ | 1 |
| Chott, A; Füreder, W; Geissler, K; Gisslinger, H; Jäger, U; Lechner, K; Valent, P; Weltermann, A | 1 |
| Balzarotti, M; Bonadonna, G; De Paoli, A; Luoni, M; Rampinelli, I; Santoro, A; Tondini, C; Valagussa, P | 1 |
| Dmoszyńska, A; Kowal, M; Lech-Marańda, E; Robak, T; Wrzesień-Kuś, A | 1 |
| Bendandi, M; Cellini, C; Magagnoli, M; Piccioli, M; Pileri, S; Poggi, S; Stefoni, V; Tani, M; Tura, S; Zinzani, PL | 1 |
| Bennett, JM; Cripe, LD; Gerad, H; Gordon, MS; Longo, W; Mazza, J; Paietta, E; Rowe, JM; Tallman, MS; Young, ML | 1 |
| Flores, E; García-Conde, J; Grau, J; Indiano, JM; Ramírez, G; Ribera, JM; Sandoval, V; Sastre, A; Tormo, M; Vercher, J | 1 |
| Błoński , JZ; Kasznicki, M; Robak, T | 1 |
| François, S; Grosbois, B; Hermine, O; Lefrère, F; Misset, JL; Panelatti, G; Troussard, X; Valensi, F; Varet, B | 1 |
| Bergeron, K; FitzGerald, DJ; Kreitman, RJ; Pastan, I; Raggio, M; Stetler-Stevenson, M; Wilson, WH | 1 |
| Jeng, M; Kelly, P; Presbury, GG; Rieman, M; Rodriguez-Galindo, C; Wang, W | 1 |
| Indrák, K; Papajík, T; Pikalová, Z; Raida, L; Zapletalová, J | 1 |
| Blakley, RL; Crom, W; Kearns, C; Mirro, J; Santana, VM; Schell, MJ | 1 |
21 review(s) available for cladribine and Recrudescence
| Article | Year |
|---|---|
The effect of cladribine tablets in people with more active multiple sclerosis: a plain language summary.
Topics: Cladribine; Humans; Immunosuppressive Agents; Language; Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting; Recurrence; Tablets | 2022 |
Relapses in people with multiple sclerosis treated with cladribine tablets followed for up to 5 years: a plain language summary.
Topics: Cladribine; Humans; Immunosuppressive Agents; Language; Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting; Recurrence; Tablets | 2022 |
Expert opinion on the long-term use of cladribine tablets for multiple sclerosis: Systematic literature review of real-world evidence.
Topics: Cladribine; Expert Testimony; Humans; Immunosuppressive Agents; Lymphocytes; Multiple Sclerosis; Recurrence; Tablets | 2023 |
[Recommendations for the use of cladribine tablets in recurring multiple sclerosis].
Topics: Cladribine; Humans; Immunosuppressive Agents; Multiple Sclerosis; Practice Guidelines as Topic; Recurrence; Tablets; Treatment Outcome | 2019 |
Long-term follow-up of Cladribine, high-dose Cytarabine, and Idarubicin as salvage treatment for relapsed acute myeloid leukemia and literature review.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Cladribine; Cytarabine; Female; Follow-Up Studies; Hematopoietic Stem Cell Transplantation; Humans; Idarubicin; Leukemia, Myeloid, Acute; Male; Middle Aged; Prognosis; Recurrence; Salvage Therapy; Survival Analysis; Treatment Outcome | 2020 |
Long-term management of multiple sclerosis patients treated with cladribine tablets: an expert opinion.
Topics: Administration, Oral; Cladribine; Clinical Trials as Topic; Drug Administration Schedule; Drug Monitoring; Expert Testimony; Humans; Immunosuppressive Agents; Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting; Practice Guidelines as Topic; Recurrence; Tablets; Treatment Outcome | 2020 |
Efficacy classification of modern therapies in multiple sclerosis.
Topics: Cladribine; Humans; Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting; Network Meta-Analysis; Recurrence | 2021 |
Treatment with disease-modifying drugs for people with a first clinical attack suggestive of multiple sclerosis.
Topics: Adjuvants, Immunologic; Cladribine; Cohort Studies; Crotonates; Disease Progression; Glatiramer Acetate; Humans; Hydroxybutyrates; Immunosuppressive Agents; Interferon beta-1a; Multiple Sclerosis; Nitriles; Publication Bias; Randomized Controlled Trials as Topic; Recurrence; Time Factors; Toluidines | 2017 |
Update on the biology and treatment options for hairy cell leukemia.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antigens, CD20; Antineoplastic Agents; B-Lymphocytes; Cladribine; Disease-Free Survival; Humans; Immunophenotyping; Immunotoxins; Indoles; Leukemia, Hairy Cell; Mutation; Pentostatin; Proto-Oncogene Proteins B-raf; Recombinant Proteins; Recurrence; Rituximab; Sulfonamides; Vemurafenib | 2014 |
Revisiting the role of cladribine in acute myeloid leukemia: an improvement on past accomplishments or more old news?
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Child; Cladribine; Clinical Trials as Topic; Humans; Leukemia, Myeloid, Acute; Recurrence; Treatment Outcome | 2015 |
Hairy cell leukemia: update and current therapeutic approach.
Topics: Antineoplastic Agents; B-Lymphocytes; Cladribine; Clinical Trials as Topic; Gene Expression; Humans; Imidazoles; Indoles; Leukemia, Hairy Cell; Mutation; Oximes; Pentostatin; Protein Kinase Inhibitors; Proto-Oncogene Proteins B-raf; Recurrence; Remission Induction; Sulfonamides; Vemurafenib | 2015 |
Long-term follow-up after purine analogue therapy in hairy cell leukaemia.
Topics: Antineoplastic Agents; B-Lymphocytes; Cladribine; Follow-Up Studies; Humans; Indoles; Leukemia, Hairy Cell; Mutation; Pentostatin; Prognosis; Proto-Oncogene Proteins B-raf; Recurrence; Remission Induction; Rituximab; Sulfonamides; Survival Analysis; Vemurafenib | 2015 |
Chemoimmunotherapy for hairy cell leukemia.
Topics: Antineoplastic Combined Chemotherapy Protocols; B-Lymphocytes; Cladribine; Humans; Immunotherapy; Leukemia, Hairy Cell; Mutation; Pentostatin; Prognosis; Proto-Oncogene Proteins B-raf; Recurrence; Remission Induction; Rituximab; Survival Analysis | 2015 |
Approach to the patient after relapse of hairy cell leukemia.
Topics: Algorithms; Antibodies, Monoclonal; Antineoplastic Agents; Cladribine; Combined Modality Therapy; Humans; Immunotoxins; Interleukin-2 Receptor alpha Subunit; Leukemia, Hairy Cell; Recombinant Proteins; Recurrence; Sialic Acid Binding Ig-like Lectin 2 | 2009 |
Magnetic resonance imaging as surrogate for clinical endpoints in multiple sclerosis: data on novel oral drugs.
Topics: Administration, Oral; Brain; Cladribine; Disability Evaluation; Disease Progression; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Magnetic Resonance Imaging; Multiple Sclerosis; Predictive Value of Tests; Propylene Glycols; Recurrence; Regression Analysis; Reproducibility of Results; Sphingosine; Time Factors; Treatment Outcome | 2011 |
Hairy cell leukemia: survival and relapse. Long-term follow-up of purine analog-based therapy and approach for relapsed disease.
Topics: ADP Ribose Transferases; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antigens, CD; Antigens, Differentiation, B-Lymphocyte; Antineoplastic Agents; Bacterial Toxins; Cell Adhesion Molecules; Cladribine; Clinical Trials as Topic; Exotoxins; Follow-Up Studies; Humans; Immunosuppressive Agents; Lectins; Leukemia, Hairy Cell; Pentostatin; Pseudomonas aeruginosa Exotoxin A; Recurrence; Remission Induction; Rituximab; Sialic Acid Binding Ig-like Lectin 2; Time Factors; Treatment Outcome; Virulence Factors | 2005 |
Cladribine in hairy cell leukemia.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Cladribine; Combined Modality Therapy; Disease-Free Survival; Genes, Immunoglobulin Heavy Chain; Humans; Italy; Leukemia, Hairy Cell; Neoplasm, Residual; Polymerase Chain Reaction; Recurrence; Remission Induction; Rituximab; Treatment Outcome | 2006 |
Pentostatin: impact on outcome in hairy cell leukemia.
Topics: Ambulatory Care; Antibiotics, Antineoplastic; Cladribine; Clinical Trials as Topic; Disease-Free Survival; Humans; Leukemia, Hairy Cell; Monitoring, Physiologic; Neoplasm, Residual; Pentostatin; Recurrence | 2006 |
2-CdA in the treatment of hairy cell leukemia: a review of long-term follow-up.
Topics: Cladribine; Follow-Up Studies; Humans; Leukemia, Hairy Cell; Recurrence; Time Factors; Treatment Outcome | 2006 |
Present status of purine analogs in the therapy of chronic lymphocytic leukemias.
Topics: Antineoplastic Agents; Cladribine; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Pentostatin; Prognosis; Recurrence; Remission Induction; Vidarabine | 1997 |
Is there a place for 2-CDA in the treatment of B-CLL?
Topics: Antineoplastic Agents; Cladribine; Clinical Trials as Topic; Drug Resistance, Neoplasm; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Recurrence; Thrombocytopenia; Vidarabine | 1997 |
39 trial(s) available for cladribine and Recrudescence
| Article | Year |
|---|---|
Long-Term Disease Stability Assessed by the Expanded Disability Status Scale in Patients Treated with Cladribine Tablets 3.5 mg/kg for Relapsing Multiple Sclerosis: An Exploratory Post Hoc Analysis of the CLARITY and CLARITY Extension Studies.
Topics: Cladribine; Humans; Immunosuppressive Agents; Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting; Recurrence; Tablets | 2021 |
Decreased relapsed rate and treatment-related mortality contribute to improved outcomes for pediatric acute myeloid leukemia in successive clinical trials.
Topics: Adolescent; Aminoglycosides; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Child; Child, Preschool; Cladribine; Clinical Protocols; Consolidation Chemotherapy; Cytarabine; Daunorubicin; Disease-Free Survival; Etoposide; Female; Gemtuzumab; Hematopoietic Stem Cell Transplantation; Humans; Induction Chemotherapy; Infant; Infant, Newborn; Leukemia, Myeloid, Acute; Male; Mitoxantrone; Neoplasm, Residual; Recurrence; Retrospective Studies; Survival Analysis; Time Factors; Treatment Outcome; Young Adult | 2017 |
Effects of Postponing Treatment in the Second Year of Cladribine Administration: Clinical Trial Simulation Analysis of Absolute Lymphocyte Counts and Relapse Rate in Patients with Relapsing-Remitting Multiple Sclerosis.
Topics: Administration, Oral; Algorithms; Cladribine; Female; Humans; Immunosuppressive Agents; Lymphocyte Count; Lymphopenia; Male; Multiple Sclerosis, Relapsing-Remitting; Practice Guidelines as Topic; Recurrence; Time Factors; Time-to-Treatment | 2019 |
Phase I study of cladribine, cytarabine, granulocyte colony stimulating factor (CLAG regimen) and midostaurin and all-trans retinoic acid in relapsed/refractory AML.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cladribine; Cytarabine; Female; fms-Like Tyrosine Kinase 3; Granulocyte Colony-Stimulating Factor; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Mutation; Nuclear Proteins; Nucleophosmin; Recurrence; Remission Induction; Staurosporine; Treatment Outcome; Tretinoin | 2014 |
Phase II, multicenter, randomized trial of CPX-351 (cytarabine:daunorubicin) liposome injection versus intensive salvage therapy in adults with first relapse AML.
Topics: Adult; Aged; Aminoglycosides; Amsacrine; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Cladribine; Cytarabine; Daunorubicin; Disease-Free Survival; Etoposide; Female; Gemtuzumab; Humans; Injections; Kaplan-Meier Estimate; Leukemia, Myeloid, Acute; Liposomes; Male; Middle Aged; Mitoxantrone; Recurrence; Remission Induction; Risk Assessment; Salvage Therapy; Treatment Outcome; Vidarabine | 2015 |
Cladribine and cytarabine in refractory multisystem Langerhans cell histiocytosis: results of an international phase 2 study.
Topics: Antineoplastic Agents; Child, Preschool; Cladribine; Cytarabine; Female; Histiocytosis, Langerhans-Cell; Humans; Immunosuppressive Agents; Infant; Langerhans Cells; Liver; Male; Recurrence; Spleen; Survival Analysis; Survival Rate; Vinblastine | 2015 |
Long-term durable remission by cladribine followed by rituximab in patients with hairy cell leukaemia: update of a phase II trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Cladribine; Disease-Free Survival; Drug Administration Schedule; Female; Follow-Up Studies; Humans; Leukemia, Hairy Cell; Male; Middle Aged; Neoplasm, Residual; Recurrence; Remission Induction; Rituximab | 2016 |
Phase I study of cladribine, cytarabine (Ara-C), granulocyte colony stimulating factor (G-CSF) (CLAG Regimen) and simultaneous escalating doses of imatinib mesylate (Gleevec) in relapsed/refractory AML.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Blast Crisis; Bone Marrow; Cladribine; Cytarabine; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Granulocyte Colony-Stimulating Factor; Humans; Imatinib Mesylate; Leukemia, Myeloid, Acute; Male; Middle Aged; Piperazines; Pyrimidines; Recurrence; Time Factors | 2008 |
Phase I/II and pharmacokinetic study of cladribine with 2-h infusion in Japanese patients with relapsed indolent B-cell lymphoma mostly pretreated with rituximab.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Cladribine; Dose-Response Relationship, Drug; Female; Humans; Infusions, Intravenous; Lymphoma, B-Cell; Male; Middle Aged; Recurrence; Rituximab | 2009 |
Combination of cladribine plus topotecan for recurrent or refractory pediatric acute myeloid leukemia.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Cladribine; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Humans; Infant; Leukemia, Myeloid, Acute; Male; Maximum Tolerated Dose; Recurrence; Retreatment; Topotecan | 2010 |
Rituximab and subcutaneous 2-chloro-2'-deoxyadenosine as therapy in untreated and relapsed Waldenström's macroglobulinemia.
Topics: Adult; Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Cladribine; Drug Administration Schedule; Female; Humans; Injections, Subcutaneous; Male; Middle Aged; Prospective Studies; Recurrence; Rituximab; Treatment Outcome; Waldenstrom Macroglobulinemia | 2011 |
Treatment of hairy cell leukemia with cladribine (2-chlorodeoxyadenosine) by subcutaneous bolus injection: a phase II study.
Topics: Adult; Aged; Antineoplastic Agents; Cladribine; Disease Progression; Female; Humans; Injections, Subcutaneous; Leukemia, Hairy Cell; Leukopenia; Male; Middle Aged; Recurrence; Survival | 2002 |
A multicenter, open, non-comparative, phase II study of the combination of cladribine (2-chlorodeoxyadenosine), cytarabine, and G-CSF as induction therapy in refractory acute myeloid leukemia - a report of the Polish Adult Leukemia Group (PALG).
Topics: Antineoplastic Combined Chemotherapy Protocols; Cladribine; Cytarabine; Disease-Free Survival; Granulocyte Colony-Stimulating Factor; Humans; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes; Prognosis; Recurrence; Remission Induction; Survival Rate | 2003 |
Reduced-intensity stem cell transplantation from an HLA-identical sibling donor in patients with myeloid malignancies.
Topics: Adult; Aged; Antilymphocyte Serum; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Busulfan; CD3 Complex; Cladribine; Disease-Free Survival; Feasibility Studies; Female; Graft vs Host Disease; Graft vs Leukemia Effect; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Transplantation; Histocompatibility Testing; HLA Antigens; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Recurrence; Time Factors; Transplantation Chimera; Transplantation, Homologous; Treatment Outcome; Vidarabine | 2004 |
Phase II trial of cladribine and cytarabine in relapsed or refractory myeloid malignancies.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Child, Preschool; Cladribine; Cytarabine; Female; Humans; Infant; Leukemia, Myeloid; Male; Recurrence; Treatment Outcome | 2004 |
Durable response but prolonged cytopenia after cladribine treatment in relapsed patients with indolent non-Hodgkin's lymphomas: results of a Japanese phase II study.
Topics: Adult; Aged; Cladribine; Female; Humans; Japan; Lymphoma, B-Cell; Lymphoma, Non-Hodgkin; Male; Middle Aged; Mycosis Fungoides; Myelodysplastic Syndromes; Neoplasms, Second Primary; Pancytopenia; Recurrence; Remission Induction; Salvage Therapy; Survival Analysis | 2004 |
Treatment of hairy cell leukemia with 2-chlorodeoxyadenosine (2-CdA): long-term follow-up of the Northwestern University experience.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Cladribine; Disease-Free Survival; Female; Follow-Up Studies; Humans; Leukemia, Hairy Cell; Male; Middle Aged; Neoplasms, Second Primary; Recurrence; Survival Analysis; Time Factors | 2005 |
Activity of cladribine combined with etoposide in heavily pretreated patients with indolent lymphoid malignancies.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cladribine; Etoposide; Female; Humans; Infections; Infusions, Intravenous; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Non-Hodgkin; Male; Middle Aged; Neutropenia; Recurrence; Survival Analysis; Treatment Outcome | 2005 |
Eradication of minimal residual disease in hairy cell leukemia.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; CD4 Lymphocyte Count; Cladribine; Female; Flow Cytometry; Humans; Leukemia, Hairy Cell; Male; Middle Aged; Neoplasm, Residual; Polymerase Chain Reaction; Recurrence; Remission Induction; Rituximab | 2006 |
Rituximab plus cladribine with or without cyclophosphamide in patients with relapsed or refractory chronic lymphocytic leukemia.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Cladribine; Cyclophosphamide; Drug Therapy, Combination; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Recurrence; Rituximab; Survival Rate | 2007 |
2-Chlorodeoxyadenosine activity in patients with untreated, indolent non-Hodgkin's lymphoma.
Topics: Actuarial Analysis; Adult; Aged; Aged, 80 and over; Anemia; Cladribine; Disease-Free Survival; Female; Humans; Lymphoma, Non-Hodgkin; Male; Middle Aged; Neoplasm Staging; Neutropenia; Recurrence; Survival Rate; Thrombocytopenia; Time Factors | 1995 |
Cladribine in the treatment of relapsed or refractory chronic lymphocytic leukemia.
Topics: Actuarial Analysis; Adult; Aged; Aged, 80 and over; Cladribine; Drug Administration Schedule; Drug Resistance; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Recurrence; Remission Induction; Survival Rate | 1995 |
Treatment of Waldenstrom's macroglobulinemia resistant to standard therapy with 2-chlorodeoxyadenosine: identification of prognostic factors.
Topics: Adult; Aged; Cladribine; Humans; Middle Aged; Neutropenia; Prognosis; Recurrence; Remission Induction; Survival Rate; Waldenstrom Macroglobulinemia | 1995 |
Primary therapy of Waldenström's macroglobulinemia with 2-chlorodeoxyadenosine.
Topics: Adult; Aged; Aged, 80 and over; CD4 Lymphocyte Count; Cladribine; Disease-Free Survival; Female; Follow-Up Studies; Humans; Infusions, Intravenous; Male; Middle Aged; Recurrence; Remission Induction; Survival Analysis; Treatment Outcome; Waldenstrom Macroglobulinemia | 1994 |
2-Chlorodeoxyadenosine in the treatment of hairy cell leukaemia: differences in response in patients with and without abdominal lymphadenopathy.
Topics: Adult; Aged; Antineoplastic Agents; Cladribine; Disease-Free Survival; Female; Humans; Leukemia, Hairy Cell; Lymphatic Diseases; Male; Middle Aged; Recurrence; Treatment Outcome | 1996 |
Clinical and laboratory studies of 2-chlorodeoxyadenosine +/- cytosine arabinoside for relapsed or refractory acute myelogenous leukemia in adults.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Arabinofuranosylcytosine Triphosphate; Cladribine; Cytarabine; Humans; Leukemia, Myeloid, Acute; Middle Aged; Recurrence | 1996 |
Intermittent 2-hour intravenous infusions of 2-chlorodeoxyadenosine in the treatment of 110 patients with refractory or previously untreated B-cell chronic lymphocytic leukemia.
Topics: Adult; Aged; Antineoplastic Agents; Cladribine; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Humans; Infusions, Intravenous; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Neoplasm Staging; Recurrence; Vidarabine | 1996 |
2-Chlorodeoxyadenosine with or without daunorubicin in relapsed or refractory acute myeloid leukemia.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Cladribine; Daunorubicin; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Recurrence; Survival Rate; Treatment Outcome | 1998 |
Bolus administration of cladribine in the treatment of Waldenström macroglobulinaemia.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Cladribine; Humans; Infusions, Intravenous; Middle Aged; Recurrence; Survival Analysis; Waldenstrom Macroglobulinemia | 1998 |
Treatment of mantle-cell lymphomas with intermittent two-hour infusion of cladribine as first-line therapy or in first relapse.
Topics: Aged; Antineoplastic Agents; Cladribine; Disease-Free Survival; Drug Administration Schedule; Female; Humans; Infusions, Intravenous; Lymphoma, Non-Hodgkin; Male; Middle Aged; Neoplasm Recurrence, Local; Prognosis; Prospective Studies; Recurrence; Survival Rate; Treatment Outcome | 1999 |
Long-term outcome of hairy cell leukemia treated with 2-chlorodeoxyadenosine.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Agents; Biopsy; Bone Marrow; Cladribine; Female; Humans; Interferon-alpha; Leukemia, Hairy Cell; Male; Middle Aged; Pentostatin; Recurrence; Remission Induction; Splenectomy; Survival Rate | 1999 |
Response to cladribine in previously treated patients with chronic lymphocytic leukaemia identified by ex vivo assessment of drug sensitivity by DiSC assay.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Cladribine; Drug Screening Assays, Antitumor; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Recurrence; Survival Analysis; Treatment Outcome | 1999 |
Intermittent 2-hour-infusion of cladribine as first-line therapy or in first relapse of progressive advanced low-grade and mantle cell lymphomas.
Topics: Adult; Aged; Antineoplastic Agents; Cladribine; Disease Progression; Disease-Free Survival; Drug Administration Schedule; Germany; Humans; Infusions, Intravenous; Lymphoma, Mantle-Cell; Lymphoma, Non-Hodgkin; Middle Aged; Recurrence; Remission Induction; Treatment Outcome | 1999 |
Fludarabine and cladribine in relapsed/refractory low-grade non-Hodgkin's lymphoma: a phase II randomized study.
Topics: Adult; Aged; Antineoplastic Agents; Cladribine; Confidence Intervals; Cross-Over Studies; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Hematologic Diseases; Humans; Infusions, Intravenous; Lymphoma, Non-Hodgkin; Male; Middle Aged; Recurrence; Survival Rate; Vidarabine | 2000 |
Phase II trial of 2-chlorodeoxyadenosine in patients with relapsed/refractory acute myeloid leukemia: a study of the Eastern Cooperative Oncology Group (ECOG), E5995.
Topics: Adult; Aged; Antineoplastic Agents; Cladribine; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Recurrence | 2000 |
Lack of efficacy of 2-chlorodeoxyadenoside in the treatment of splenic lymphoma with villous lymphocytes.
Topics: Adenosine Triphosphate; Aged; Antineoplastic Agents; Cladribine; Cohort Studies; Disease-Free Survival; Female; Follow-Up Studies; Humans; Lymphoma, B-Cell; Male; Middle Aged; Recurrence; Splenic Neoplasms; Therapeutic Equivalency; Treatment Outcome | 2000 |
Efficacy of the anti-CD22 recombinant immunotoxin BL22 in chemotherapy-resistant hairy-cell leukemia.
Topics: Adult; Aged; Antibodies; Antineoplastic Agents; Cladribine; Dose-Response Relationship, Drug; Drug Resistance; Enterotoxins; Exotoxins; Female; Hemolytic-Uremic Syndrome; Humans; Immunotoxins; Leukemia, Hairy Cell; Male; Middle Aged; Pseudomonas; Recurrence; Remission Induction | 2001 |
Treatment of children with Langerhans cell histiocytosis with 2-chlorodeoxyadenosine.
Topics: Child; Child, Preschool; Cladribine; Cohort Studies; Disease-Free Survival; Histiocytosis, Langerhans-Cell; Humans; Immunosuppressive Agents; Infant; Recurrence; Remission Induction; Treatment Outcome | 2002 |
2-Chlorodeoxyadenosine produces a high rate of complete hematologic remission in relapsed acute myeloid leukemia.
Topics: 2-Chloroadenosine; Acute Disease; Adolescent; Adult; Antineoplastic Agents; Bone Marrow Transplantation; Child; Child, Preschool; Cladribine; Combined Modality Therapy; Deoxyadenosines; Drug Evaluation; Female; Humans; Infusions, Intravenous; Leukemia, Myeloid; Male; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Recurrence; Regression Analysis; Remission Induction | 1992 |
80 other study(ies) available for cladribine and Recrudescence
| Article | Year |
|---|---|
[Moxetumomab pasudotox-Third line in Hairy cell leukemia].
Topics: Antineoplastic Agents; Bacterial Toxins; Cladribine; Exotoxins; Humans; Induction Chemotherapy; Leukemia, Hairy Cell; Pentostatin; Recurrence; Retreatment; Sialic Acid Binding Ig-like Lectin 2 | 2021 |
Risk of fingolimod rebound after switching to cladribine or rituximab in multiple sclerosis.
Topics: Cladribine; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting; Recurrence; Retrospective Studies; Rituximab | 2022 |
Finnish multiple sclerosis patients treated with cladribine tablets: a nationwide registry study.
Topics: Adult; Cladribine; Cohort Studies; Fingolimod Hydrochloride; Finland; Humans; Immunosuppressive Agents; Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting; Recurrence; Registries; Tablets | 2022 |
[Recurrent and Refractory Langerhans Cell Histiocytosis in Children Treated with the Combination of Cladribine and Cytarabine].
Topics: Child; Cladribine; Cytarabine; Histiocytosis, Langerhans-Cell; Humans; Recurrence; Retrospective Studies | 2022 |
Immunological consequences of cladribine treatment in multiple sclerosis: A real-world study.
Topics: CD8-Positive T-Lymphocytes; Cladribine; Humans; Immunosuppressive Agents; Lymphopenia; Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting; Prospective Studies; Recurrence | 2022 |
Long-term follow-up of cladribine treatment in hairy cell leukemia: 30-year experience in a multicentric Italian study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Cladribine; Follow-Up Studies; Humans; Leukemia, Hairy Cell; Middle Aged; Recurrence; Remission Induction; Retrospective Studies; Treatment Outcome; Young Adult | 2022 |
Prediction of relapse activity when switching to cladribine for multiple sclerosis.
Topics: Chronic Disease; Cladribine; Fingolimod Hydrochloride; Humans; Immunologic Factors; Immunosuppressive Agents; Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting; Natalizumab; Recurrence | 2023 |
Economic evaluation of cladribine tablets in high disease activity (HDA) relapsing multiple sclerosis (RMS) patients in Lebanon.
Topics: Cladribine; Cost-Benefit Analysis; Humans; Immunosuppressive Agents; Lebanon; Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting; Recurrence; Tablets | 2022 |
Comparing switch to ocrelizumab, cladribine or natalizumab after fingolimod treatment cessation in multiple sclerosis.
Topics: Cladribine; Cohort Studies; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting; Natalizumab; Recurrence; Treatment Outcome; Withholding Treatment | 2022 |
Cladribine and pregnancy in women with multiple sclerosis: The first cohort study.
Topics: Cladribine; Cohort Studies; Female; Humans; Immunosuppressive Agents; Infant, Newborn; Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting; Pregnancy; Pregnancy Outcome; Recurrence | 2023 |
Comparative effectiveness of cladribine tablets versus other oral disease-modifying treatments for multiple sclerosis: Results from MSBase registry.
Topics: Cladribine; Dimethyl Fumarate; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting; Recurrence; Registries; Retrospective Studies; Tablets | 2023 |
Clinical outcomes and prognostic risk factors of Langerhans cell histiocytosis in children: Results from the BCH-LCH 2014 protocol study.
Topics: Child; Child, Preschool; Cladribine; Histiocytosis, Langerhans-Cell; Humans; Prognosis; Recurrence; Retrospective Studies; Risk Factors; Treatment Outcome; Vindesine | 2023 |
Cladribine- and decitabine-containing conditioning regimen has a low post-transplant relapse rate in patients with relapsed or refractory acute myeloid leukemia and high-risk myelodysplastic syndrome.
Topics: Chronic Disease; Cladribine; Decitabine; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes; Recurrence; Retrospective Studies | 2023 |
Serum Neurofilament Light Chain as Biomarker for Cladribine-Treated Multiple Sclerosis Patients in a Real-World Setting.
Topics: Biomarkers; Cladribine; Humans; Intermediate Filaments; Multiple Sclerosis; Neurofilament Proteins; Prospective Studies; Recurrence | 2023 |
Effectiveness and safety profile of cladribine in an Italian real-life cohort of relapsing-remitting multiple sclerosis patients: a monocentric longitudinal observational study.
Topics: Cladribine; Drug-Related Side Effects and Adverse Reactions; Humans; Immunosuppressive Agents; Lymphopenia; Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting; Recurrence | 2023 |
Safety and effectiveness of cladribine tablets for multiple sclerosis: Results from a single-center real-world cohort.
Topics: Adult; Cladribine; Female; Humans; Immunosuppressive Agents; Male; Middle Aged; Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting; Recurrence; Retrospective Studies; Tablets | 2023 |
Comparative effectiveness of cladribine tablets versus fingolimod in the treatment of highly active multiple sclerosis: A real-world study.
Topics: Cladribine; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting; Recurrence; Retrospective Studies; Tablets | 2023 |
Real-world treatment patterns and effectiveness of cladribine tablets in patients with relapsing forms of multiple sclerosis in the United States.
Topics: Adrenal Cortex Hormones; Adult; Cladribine; Female; Humans; Immunosuppressive Agents; Male; Middle Aged; Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting; Recurrence; Tablets; United States | 2023 |
Severe fingolimod rebound syndrome after switching to cladribine treatment.
Topics: Adult; Cladribine; Female; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Magnetic Resonance Imaging; Multiple Sclerosis, Relapsing-Remitting; Recurrence | 2020 |
Severe skin reactions associated with cladribine in people with multiple sclerosis.
Topics: Cladribine; Humans; Immunosuppressive Agents; Multiple Sclerosis; Neoplasms; Recurrence | 2020 |
Egyptian experience in Langerhans cells histiocytosis: frequent multisystem affection and reactivation rates.
Topics: Child; Child, Preschool; Cladribine; Cyclosporine; Disease Progression; Egypt; Female; Histiocytosis, Langerhans-Cell; Humans; Infant; Langerhans Cells; Liver; Lymph Nodes; Lymphohistiocytosis, Hemophagocytic; Male; Recurrence; Retrospective Studies; Risk Factors; Survival Rate; Treatment Outcome | 2020 |
Efficacy of cladribine tablets in high disease activity patients with relapsing multiple sclerosis:
Topics: Cladribine; Humans; Immunosuppressive Agents; Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting; Recurrence; Tablets | 2021 |
Analysis of frequency and severity of relapses in multiple sclerosis patients treated with cladribine tablets or placebo: The CLARITY and CLARITY Extension studies.
Topics: Cladribine; Humans; Immunosuppressive Agents; Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting; Recurrence; Tablets | 2022 |
Cladribine versus fingolimod, natalizumab and interferon β for multiple sclerosis.
Topics: Adult; Cladribine; Cohort Studies; Female; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Interferon-beta; Male; Middle Aged; Multiple Sclerosis, Relapsing-Remitting; Natalizumab; Propensity Score; Recurrence; Treatment Outcome | 2018 |
Oral Disease-Modifying Treatments for Relapsing Multiple Sclerosis: A Likelihood to Achieve No Evidence of Disease Activity or Harm Analysis.
Topics: Adolescent; Adult; Aged; Cladribine; Clinical Trials, Phase III as Topic; Crotonates; Dimethyl Fumarate; Drug-Related Side Effects and Adverse Reactions; Female; Fingolimod Hydrochloride; Humans; Hydroxybutyrates; Immunosuppressive Agents; Male; Middle Aged; Multiple Sclerosis; Nitriles; Recurrence; Toluidines; Young Adult | 2018 |
Analysis of Efficacy and Prognostic Factors of CLAG Treatment in Chinese Patients with Refractory or Relapsed Acute Myeloid Leukemia.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; China; Cladribine; Cytarabine; Drug Administration Schedule; Female; Granulocyte Colony-Stimulating Factor; Humans; Leukemia, Myeloid, Acute; Logistic Models; Male; Middle Aged; Neutropenia; Prognosis; Proportional Hazards Models; Recurrence; Survival Rate; Treatment Outcome | 2019 |
Benefit-risk Assessment of Cladribine Using Multi-criteria Decision Analysis (MCDA) for Patients With Relapsing-remitting Multiple Sclerosis.
Topics: Alemtuzumab; Cladribine; Crotonates; Decision Support Techniques; Dimethyl Fumarate; Fingolimod Hydrochloride; Humans; Hydroxybutyrates; Immunosuppressive Agents; Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting; Natalizumab; Nitriles; Recurrence; Risk Assessment; Toluidines | 2019 |
Clinical characteristics and long-term outcome of young hairy cell leukemia patients treated with cladribine: a single-institution series.
Topics: Adult; Aged; Antineoplastic Agents; Cladribine; Female; Humans; Leukemia, Hairy Cell; Male; Middle Aged; Neoplasms, Second Primary; Recurrence; Remission Induction; Retreatment; Treatment Outcome; Young Adult | 2014 |
BRAF(V600E) mutation in a histiocytic sarcoma arising from hairy cell leukemia.
Topics: Aged; Antineoplastic Agents; Cell Proliferation; Cladribine; Flow Cytometry; Histiocytic Sarcoma; Humans; Leukemia, Hairy Cell; Male; Mutation; Proto-Oncogene Proteins B-raf; Recurrence; Remission Induction | 2014 |
[Cladribine treatment of repeatedly-relapsed Langerhans cell histiocytosis: a case report and literature review].
Topics: Child; Cladribine; Histiocytosis, Langerhans-Cell; Humans; Immunosuppressive Agents; Male; Recurrence; Skin | 2015 |
Hairy cell leukemia.
Topics: Antineoplastic Agents; B-Lymphocytes; Cladribine; Disease Management; Drug Resistance, Neoplasm; Female; Gene Expression; Humans; Indoles; Leukemia, Hairy Cell; Male; Mutation; Pentostatin; Proto-Oncogene Proteins B-raf; Recurrence; Remission Induction; Sex Factors; Sulfonamides; Vemurafenib | 2015 |
[Efficacy and safety analysis of the combination of cladribine, cytarabine, granulocyte colonystimulating factor (CLAG) regime in patients with refractory or relapsed acute myeloid leukemia].
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cladribine; Cytarabine; Female; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Neutropenia; Recurrence; Retrospective Studies; Young Adult | 2016 |
Comparison of cladribine- and fludarabine-based induction chemotherapy in relapsed or refractory acute myeloid leukaemia.
Topics: Adult; Aged; Aged, 80 and over; Allografts; Antineoplastic Combined Chemotherapy Protocols; Cladribine; Combined Modality Therapy; Cytarabine; Disease-Free Survival; Drug Evaluation; Drug Resistance, Neoplasm; Female; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Transplantation; Humans; Kaplan-Meier Estimate; Leukemia, Myeloid, Acute; Male; Middle Aged; Proportional Hazards Models; Recurrence; Retrospective Studies; Salvage Therapy; Treatment Outcome; Vidarabine | 2016 |
Cladribine, cytarabine and idarubicin (CLA-Ida) salvage chemotherapy in relapsed acute myeloid leukemia (AML).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cladribine; Cytarabine; Female; Hematopoietic Stem Cell Transplantation; Humans; Idarubicin; Kaplan-Meier Estimate; Leukemia, Myeloid, Acute; Male; Middle Aged; Recurrence; Remission Induction; Salvage Therapy; Transplantation, Homologous; Treatment Outcome; Young Adult | 2017 |
Rituximab in patients with hairy cell leukemia relapsing after treatment with 2-chlorodeoxyadenosine (SAKK 31/98).
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Cladribine; Disease-Free Survival; Female; Follow-Up Studies; Humans; Leukemia, Hairy Cell; Male; Recurrence; Rituximab; Treatment Outcome | 2008 |
Treatment of refractory Langerhans cell histiocytosis (LCH) with a combination of 2-chlorodeoxyadenosine and cytosine arabinoside.
Topics: Antineoplastic Combined Chemotherapy Protocols; Child, Preschool; Cladribine; Cytarabine; Histiocytosis, Langerhans-Cell; Humans; Infant; Infant, Newborn; Infusions, Intravenous; Radiography; Recurrence; Survival Rate | 2009 |
Long-term follow-up of 233 patients with hairy cell leukaemia, treated initially with pentostatin or cladribine, at a median of 16 years from diagnosis.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Cladribine; Female; Follow-Up Studies; Humans; Kaplan-Meier Estimate; Leukemia, Hairy Cell; Male; Middle Aged; Pentostatin; Recurrence; Remission Induction; Rituximab; Survival Rate; Treatment Outcome | 2009 |
Cladribine in the treatment of acute myeloid leukemia: a single-institution experience.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cladribine; Female; Humans; Injections, Subcutaneous; Leukemia, Myeloid, Acute; Male; Middle Aged; Recurrence; Retrospective Studies; Salvage Therapy; Treatment Outcome; Young Adult | 2009 |
Cladribine treatment in two-hour intravenous infusion for previously-treated low grade B-cell lymphoma: a pilot study.
Topics: Adult; Aged; Ambulatory Care; Antineoplastic Agents; Asian People; Cladribine; Female; Humans; Infusions, Intravenous; Japan; Lymphoma, B-Cell; Male; Middle Aged; Pilot Projects; Recurrence; Retrospective Studies | 2009 |
Severe persistent bone marrow failure following therapy with 2-chlorodeoxyadenosine for relapsing juvenile xanthogranuloma of the brain.
Topics: Anemia, Aplastic; Bone Marrow Diseases; Bone Marrow Failure Disorders; Bone Marrow Transplantation; Brain Diseases; Child; Cladribine; Hemoglobinuria, Paroxysmal; Humans; Immunosuppressive Agents; Male; Prognosis; Recurrence; Transfusion Reaction; Xanthogranuloma, Juvenile | 2012 |
Rituximab with pentostatin or cladribine: an effective combination treatment for hairy cell leukemia after disease recurrence.
Topics: Adult; Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Cladribine; Female; Humans; Leukemia, Hairy Cell; Male; Middle Aged; Pentostatin; Recurrence; Retrospective Studies; Rituximab; Salvage Therapy; Treatment Outcome | 2011 |
My treatment approach to hairy cell leukemia.
Topics: Antibiotic Prophylaxis; Antineoplastic Agents; Biopsy; Bone Marrow; Cladribine; Humans; Interferons; Leukemia, Hairy Cell; Pentostatin; Recurrence; Remission Induction; Survival Analysis; Treatment Outcome | 2012 |
[Lenalidomide induced therapeutic response in a patient with aggressive multi-system Langerhans cell histiocytosis resistant to 2-chloro-deoxyadenosine and early relapsing after high-dose BEAM chemotherapy with autologous peripheral blood stem cell transp
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cladribine; Combined Modality Therapy; Cytarabine; Drug Resistance, Neoplasm; Etoposide; Histiocytosis, Langerhans-Cell; Humans; Lenalidomide; Male; Melphalan; Peripheral Blood Stem Cell Transplantation; Recurrence; Remission Induction; Thalidomide; Transplantation, Autologous | 2012 |
Topotecan exposure estimation in pediatric acute myeloid leukemia supported by LC-MS-based drug monitoring and pharmacokinetic analysis.
Topics: Age Factors; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Calibration; Chromatography, Liquid; Chromatography, Reverse-Phase; Cladribine; Drug Dosage Calculations; Drug Monitoring; Female; Half-Life; Humans; Leukemia, Myeloid, Acute; Limit of Detection; Linear Models; Metabolic Clearance Rate; Recurrence; Reference Standards; Reproducibility of Results; Spectrometry, Mass, Electrospray Ionization; Topoisomerase I Inhibitors; Topotecan | 2012 |
Treatment of hairy cell leukemia: long-term results in a developing country.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Cladribine; Developing Countries; Female; Humans; Interferon-alpha; Leukemia, Hairy Cell; Longitudinal Studies; Male; Mexico; Middle Aged; Recurrence; Remission Induction; Survival Analysis | 2012 |
[Treatment for recurrent hairy cell leukemia].
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Cladribine; Combined Modality Therapy; Female; Humans; Interferon-alpha; Leukemia, Hairy Cell; Male; Middle Aged; Recurrence; Remission Induction; Rituximab; Splenectomy | 2012 |
Recurrent Langerhans cell histiocytosis of the mandible.
Topics: Antimetabolites; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Biopsy; Child; Cladribine; Curettage; Eosinophilic Granuloma; Female; Glucocorticoids; Histiocytosis, Langerhans-Cell; Humans; Mandibular Diseases; Mercaptopurine; Methotrexate; Prednisolone; Recurrence; Tomography, X-Ray Computed; Vinblastine | 2013 |
Re-treatment with cladribine-based regimens in relapsed patients with B-cell chronic lymphocytic leukemia. Efficacy and toxicity in comparison with previous treatment.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cladribine; Cyclophosphamide; Disease-Free Survival; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Mitoxantrone; Prednisone; Recurrence; Survival Analysis; Treatment Outcome | 2002 |
Cellular drug resistance in childhood acute myeloid leukemia is related to chromosomal abnormalities.
Topics: Acute Disease; Adolescent; Antibiotics, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Chromosome Aberrations; Chromosome Inversion; Chromosomes, Human; Cladribine; Cytarabine; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Etoposide; Female; Humans; Infant; Leukemia, Myeloid; Male; Neoplastic Stem Cells; Recurrence; Remission Induction; Tetrazolium Salts; Thiazoles; Translocation, Genetic; Trisomy | 2002 |
Rituximab: a useful drug for a repeatedly relapsed hairy cell leukemia patient.
Topics: Adult; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Cladribine; Humans; Interferon-alpha; Leukemia, Hairy Cell; Male; Pentostatin; Recurrence; Remission Induction; Rituximab; Salvage Therapy | 2002 |
Impact of graft-versus-host disease in reduced-intensity stem cell transplantation (RIST) for patients with haematological malignancies.
Topics: Acute Disease; Adolescent; Adult; Aged; Busulfan; Chronic Disease; Cladribine; Cyclophosphamide; Disease-Free Survival; Graft vs Host Disease; Hematologic Neoplasms; Humans; Immunosuppressive Agents; Middle Aged; Proportional Hazards Models; Recurrence; Stem Cell Transplantation; Survival Rate; Thyroglobulin; Transplantation Conditioning; Vidarabine; Whole-Body Irradiation | 2003 |
Hepatosplenic gamma delta T-cell lymphoma with leukemic phase successfully treated with 2-chlorodeoxyadenosine.
Topics: Adult; Antineoplastic Agents; Cladribine; Female; Hepatomegaly; Humans; Lymphoma, T-Cell; Receptors, Antigen, T-Cell, gamma-delta; Recurrence; Remission Induction; Splenomegaly | 2002 |
Alemtuzumab (Campath 1H) in hairy cell leukaemia relapsing after rituximab treatment.
Topics: Alemtuzumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Monoclonal, Murine-Derived; Antibodies, Neoplasm; Antimetabolites, Antineoplastic; Antineoplastic Agents; Cladribine; Combined Modality Therapy; Drug Resistance, Neoplasm; Humans; Immunization, Passive; Interferon-alpha; Leukemia, Hairy Cell; Recurrence; Remission Induction; Rituximab; Splenectomy | 2004 |
In vitro sensitivity of leukemic cells to nucleoside derivatives in childhood acute leukemias: good activity in leukemic relapses.
Topics: Adolescent; Adult; Antineoplastic Agents; Cell Death; Child; Child, Preschool; Cladribine; Cytarabine; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Female; Humans; Infant; Infant, Newborn; Leukemia, Myeloid; Male; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Recurrence; Tumor Cells, Cultured; Vidarabine | 2005 |
Concomitant hairy cell and acute myeloid leukemia.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Cladribine; Cytarabine; Daunorubicin; Genetic Predisposition to Disease; Humans; Leukemia, Hairy Cell; Leukemia, Myeloid, Acute; Male; Middle Aged; Neoplasms, Second Primary; Recurrence; Stem Cell Transplantation | 2006 |
[Successful salvage therapy with cladribine and rituximab for a patient with a relapsed Asian variant of intravascular large B-cell lymphoma].
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Cladribine; Drug Administration Schedule; Humans; Lymphoma, B-Cell; Male; Recurrence; Rituximab; Salvage Therapy; Vascular Neoplasms | 2006 |
The role of rituximab in combination with pentostatin or cladribine for the treatment of recurrent/refractory hairy cell leukemia.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Cladribine; Female; Humans; Leukemia, Hairy Cell; Male; Middle Aged; Pentostatin; Recurrence; Rituximab | 2007 |
Cladribine combined with high doses of arabinoside cytosine, mitoxantrone, and G-CSF (CLAG-M) is a highly effective salvage regimen in patients with refractory and relapsed acute myeloid leukemia of the poor risk: a final report of the Polish Adult Leukem
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cladribine; Cytarabine; Female; Granulocyte Colony-Stimulating Factor; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Mitoxantrone; Multivariate Analysis; Odds Ratio; Poland; Recurrence; Salvage Therapy; Stem Cell Transplantation; Treatment Outcome | 2008 |
Hepatosplenic gammadelta T-cell lymphoma successfully treated with a combination of alemtuzumab and cladribine.
Topics: Adult; Alemtuzumab; Anemia, Hemolytic; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Monoclonal, Murine-Derived; Antibodies, Neoplasm; Antigens, CD; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Blood Transfusion; Cladribine; Cyclophosphamide; Doxorubicin; Female; Humans; Liver Neoplasms; Lymphoma, T-Cell; Neutropenia; Prednisolone; Receptors, Antigen, T-Cell, gamma-delta; Recurrence; Remission Induction; Rituximab; Splenic Neoplasms; Vincristine | 2008 |
2Chlorodeoxyadenosine therapy of patients with Waldenström macroglobulinemia previously treated with fludarabine.
Topics: Aged; Antimetabolites, Antineoplastic; Cladribine; Drug Resistance; Female; Humans; Male; Middle Aged; Recurrence; Treatment Outcome; Vidarabine Phosphate; Waldenstrom Macroglobulinemia | 1994 |
[Successful treatment of a case of cutaneous Langerhans cell granulomatosis with 2-chlorodeoxyadenosine and thalidomide].
Topics: Aged; Cladribine; Drug Therapy, Combination; Female; Histiocytosis, Langerhans-Cell; Humans; Immunosuppressive Agents; Recurrence; Skin; Skin Diseases; Thalidomide | 1995 |
High complete remission rate from 2-chloro-2'-deoxyadenosine in previously treated patients with B-cell chronic lymphocytic leukemia: response predicted by rapid decrease of blood lymphocyte count.
Topics: Adult; Aged; Aged, 80 and over; Bone Marrow; Cladribine; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Leukocyte Count; Lymphocytes; Male; Middle Aged; Recurrence; Remission Induction; Survival Rate | 1993 |
Delayed reactivation of hepatitis B infection after cladribine.
Topics: Aged; Cladribine; Hepatitis B; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Recurrence | 1996 |
2-Chlorodeoxyadenosine (2-CdA) in the treatment of patients with relapsed chronic lymphocytic leukemia.
Topics: Adult; Aged; Antineoplastic Agents; Cladribine; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Recurrence | 1995 |
High response rates with short infusional 2-chlorodeoxyadenosine in de novo and relapsed low-grade lymphoma. Australian and New Zealand Lymphoma Study Group.
Topics: Adult; Aged; Antineoplastic Agents; Cladribine; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Leukopenia; Lymphoma, Follicular; Lymphoma, Non-Hodgkin; Male; Middle Aged; Opportunistic Infections; Recurrence; Survival Analysis; Thrombocytopenia; Treatment Outcome | 1996 |
2-Chlorodeoxyadenosine in the treatment of relapsed/refractory chronic lymphoproliferative disorders.
Topics: Adult; Aged; Antineoplastic Agents; Chronic Disease; Cladribine; Female; Humans; Lymphoproliferative Disorders; Male; Middle Aged; Recurrence; Treatment Outcome | 1997 |
Treatment of hairy-cell leukemia with cladribine: response, toxicity, and long-term follow-up.
Topics: Adult; Aged; Antineoplastic Agents; Cladribine; Disease Progression; Female; Follow-Up Studies; Humans; Leukemia, Hairy Cell; Male; Middle Aged; Neutropenia; Phenotype; Recurrence; Remission Induction | 1997 |
Hairy cell leukemia-variant treated with 2-chlorodeoxyadenosine--a report of three cases.
Topics: Aged; Antigens, Surface; Antineoplastic Agents; Cladribine; Drug Resistance, Neoplasm; Female; Humans; Leukemia, Hairy Cell; Male; Middle Aged; Recurrence; Remission Induction; Spleen; Treatment Outcome | 1997 |
2-Chlorodeoxyadenosine (2-CDA) for the treatment of refractory or recurrent Langerhans cell histiocytosis (LCH) in pediatric patients.
Topics: Adolescent; Child, Preschool; Cladribine; Female; Histiocytosis, Langerhans-Cell; Humans; Immunosuppressive Agents; Prospective Studies; Radiography; Recurrence; Skull | 1997 |
Ex vivo evidence of lymphocyte apoptosis in hairy cell leukemia, induced by 2-chlorodeoxyadenosine treatment.
Topics: Annexin A5; Apoptosis; Cladribine; Flow Cytometry; Humans; Injections, Intravenous; Leukemia, Hairy Cell; Lymphocyte Count; Lymphocyte Subsets; Lymphocytes; Recurrence | 1998 |
The role of 2-chlorodeoxyadenosine in the treatment of patients with refractory angioimmunoblastic lymphadenopathy with dysproteinemia.
Topics: Adult; Aged; Blood Protein Disorders; Chronic Disease; Cladribine; Female; Humans; Immunoblastic Lymphadenopathy; Immunosuppressive Agents; Male; Middle Aged; Recurrence; Retrospective Studies | 1999 |
2-Chlorodeoxyadenosine (Cladribine) in the treatment of patients with chronic lymphocytic leukemia 55 years old and younger.
Topics: Adult; Alopecia; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Chemical and Drug Induced Liver Injury; Cladribine; Cyclophosphamide; Doxorubicin; Drug Eruptions; Drug Resistance, Neoplasm; Female; Fever; Hematologic Diseases; Humans; Immunophenotyping; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Prednisone; Recurrence; Remission Induction; Salvage Therapy; Treatment Outcome; Vincristine | 1999 |
Minimal residual disease in patients with hairy cell leukemia in complete remission treated with 2-chlorodeoxyadenosine or 2-deoxycoformycin and prediction of early relapse.
Topics: Adult; Aged; Aged, 80 and over; Antibiotics, Antineoplastic; Antineoplastic Agents; Bone Marrow; Cladribine; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Female; Humans; Immunohistochemistry; Leukemia, Hairy Cell; Male; Middle Aged; Neoplasm, Residual; Pentostatin; Recurrence; Remission Induction | 1999 |
Long-term follow-up of patients with hairy cell leukaemia after treatment with pentostatin or cladribine.
Topics: Adult; Aged; Aged, 80 and over; Antibiotics, Antineoplastic; Antineoplastic Agents; Cladribine; Female; Follow-Up Studies; Humans; Leukemia, Hairy Cell; Male; Middle Aged; Pentostatin; Recurrence; Survival Analysis | 1999 |
Treatment of hairy cell leukemia with cladribine (2-chlorodeoxyadenosine).
Topics: Adult; Antibiotics, Antineoplastic; Antineoplastic Agents; Cladribine; Data Interpretation, Statistical; Female; Follow-Up Studies; Humans; Immunosuppressive Agents; Interferon-alpha; Leukemia, Hairy Cell; Male; Middle Aged; Pentostatin; Recurrence; Remission Induction; Splenectomy; Time Factors | 1999 |
Combination regimen of cladribine (2-chlorodeoxyadenosine), cytarabine and G-CSF (CLAG) as induction therapy for patients with relapsed or refractory acute myeloid leukemia.
Topics: Acute Disease; Adult; Alopecia; Antineoplastic Combined Chemotherapy Protocols; Cladribine; Cytarabine; Disease-Free Survival; Drug Evaluation; Female; Fever; Granulocyte Colony-Stimulating Factor; Humans; Infections; Leukemia, Myeloid; Male; Middle Aged; Neutropenia; Recurrence; Remission Induction; Survival Rate; Treatment Outcome | 2000 |
Long-term follow-up of hairy cell leukemia patients treated with 2-chlorodeoxyadenosine.
Topics: Adult; Aged; Cladribine; Disease-Free Survival; Drug Evaluation; Female; Follow-Up Studies; Humans; Leukemia, Hairy Cell; Male; Middle Aged; Recurrence; Survival Rate; Treatment Outcome | 2000 |
[Results of treatment with 2-chlorodeoxyadenosine in refractory or relapsed Langerhans cell histiocytosis. Study of 9 patients].
Topics: Adolescent; Adult; Child; Cladribine; Female; Histiocytosis, Langerhans-Cell; Humans; Immunosuppressive Agents; Male; Middle Aged; Recurrence | 2001 |
Does intensive treatment with high dose chlorambucil and prednisone as first line and cladribine as second line influence the survival of the patients with chronic lymphocytic leukemia?
Topics: Actuarial Analysis; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cause of Death; Chlorambucil; Cladribine; Cohort Studies; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Prednisone; Recurrence; Retrospective Studies; Survival Rate | 2001 |
[Therapeutic effectiveness of cladribine and cellular immunodeficiency--related effects in hairy-cell leukemia?].
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; CD4 Lymphocyte Count; CD56 Antigen; CD8-Positive T-Lymphocytes; Cladribine; Disease Progression; Female; Humans; Immunosuppressive Agents; Leukemia, Hairy Cell; Lymphocytes; Male; Middle Aged; Recurrence; Remission Induction | 2002 |